Liposomal Dry Powder Inhaler for the Treatment of Non Small Cell Lung Carcinoma NSCLC

dc.contributor.guidePatel, Pinkal
dc.coverage.spatial
dc.creator.researcherPatil, Mansing
dc.date.accessioned2023-10-22T09:52:22Z
dc.date.available2023-10-22T09:52:22Z
dc.date.awarded2023
dc.date.completed2023
dc.date.registered2018
dc.description.abstractThe death rate in lung carcinoma patients is high in overall cancer-related deaths worldwide. Non-small cell lung carcinoma (NSCLC) is the major type of lung carcinoma, about 80-85% of lung carcinoma is NSCLC. The epidermal growth factor receptor (EGFR) is newlinea transmembrane protein that mostly overexpression in NSCLC. The function of EGFR the receptor involves cell proliferation, regulating apoptosis, cell migration, and, adhesion. So, the drug that directly binds with this receptor is important to increase the survival time by reducing uneven toxicity and increasing patient compliance. Osimertinib Mesylate is a thirdgeneration newlinefirst-line reversible tyrosine kinase family of EGFR inhibitors and is considered the primary therapy of patients having NSCLC. The present work aim to develop a nanocarrier-based dry powder inhaler of Osimertinib Mesylate for the effective treatment of newlineNSCLC by the inhalation route. The present research work utilized liposomes as nanocarriers for the targeted delivery of Osimertinib Mesylate to lung cancer by the inhalation route. Osimertinib Mesylate-encapsulated liposomes were fabricated by the thin film hydration method. Formulation optimization was performed by a Response surface methodology approach. Further, Osimertinib Mesylate-loaded liposomal dispersions were converted into dry form by a validated lyophilization technique. Finally, the Osimertinib Mesylate-loaded liposomal dry powder inhaler (LDPI) was characterized. Results of the studies indicated that newlinenanocarrier systems are significantly better than the plain drug solution (conventional) newlineconcerning the targeted delivery, controlled release, higher tumor penetration capacity, and higher cytotoxic potential of an encapsulated agent. Thus, the formulated Osimertinib Mesylate-loaded PEGylated LDPI can extend the overall survival time in lung cancer patients by accurately targeting the disease location to reduce uneven side effects via the pulmonary route.
dc.description.note
dc.format.accompanyingmaterialDVD
dc.format.dimensions
dc.format.extent
dc.identifier.urihttp://hdl.handle.net/10603/520144
dc.languageEnglish
dc.publisher.institutionPharmaceutical Sciences
dc.publisher.placeVadodara
dc.publisher.universityParul University
dc.relation
dc.rightsuniversity
dc.source.universityUniversity
dc.subject.keywordClinical Pre Clinical and Health
dc.subject.keywordDry powder inhaler (DPI)
dc.subject.keywordLiposomes
dc.subject.keywordLyophilization
dc.subject.keywordNon-small cell lung cancer (NSCLC)
dc.subject.keywordOsimertinib Mesylate
dc.subject.keywordPharmacology and Pharmacy
dc.subject.keywordPharmacology and Toxicology
dc.subject.keywordThin film hydration method
dc.titleLiposomal Dry Powder Inhaler for the Treatment of Non Small Cell Lung Carcinoma NSCLC
dc.title.alternative
dc.type.degreePh.D.

Files

Original bundle

Now showing 1 - 5 of 12
Loading...
Thumbnail Image
Name:
01_title.pdf
Size:
208.02 KB
Format:
Adobe Portable Document Format
Description:
Attached File
Loading...
Thumbnail Image
Name:
02_prelim pages.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
03_content.pdf
Size:
578.82 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
04_abstract.pdf
Size:
515.15 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
05_chapter 1.pdf
Size:
2.43 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description: